Japanese Poster Session

[Pj-021] Neuroimmunology (MS and disease modifying therapy1)

Wed. May 22, 2019 5:20 PM - 6:35 PM Poster Exhibition (Osaka International Convention Center 3F Event Hall)

Chair:Chiyoko Nohara(Tokyo Metropolitan Health and Medical Treatment Corporation Ebara Hospital)

+Add all to schedule

[Pj-021-1] The experience of using dimethyl fumarate in the patients with multiple sclerosis in our hospital

Mizuki Kitamura¹, Takuya Sasaki¹, Takahiro Nakayama¹, Tomoki Nakamori², Ichiro Imafuku¹ (1.Department of Neurology, Yokohama Rosai Hospital, 2.Department of Emergency and Disaster Medicine, Emergency and Critical Care Center, Yokohama Rosai Hospital)

[Pj-021-2] Experience of using dimethyl fumarate in multiple sclerosis

Masanori Mizuno, Masako Suzuki, Yasuo Terayama (Department of Neurology and Gerontology, Iwate Medical University)

[Pj-021-3] Clinical appearance after switcing from fingollimod to dimethyl fumarate for multiple scleosis

Moemi Yamada¹, Kazunori Sato¹, Atsushi Kawashima¹, Takuya Higashi³, Yuuei Miyazaki², Masaaki Niino², Toshiyuki Fukazawa¹ (1.Sapporo Neurology Hospital, 2.Department of Clinical Research, Hokkaido Medical Center, 3.Sapporo Neurology Clinic)

[Pj-021-4] Analysis of cases of multiple sclerosis treated with disease-modifying drugs

Masayuki Mizuno, Gohei Yamada, Toyohiro Sato, Teppei Fujioka, Daisuke Kato, Shoji Kawashima, Takanari Toyoda, Yoshino Ueki, Kenji Okita, Noriyuki Matsukawa (Department of Neurology and Neuroscience, Nagoya City University Graduate School of Medical Sciences)

[Pj-021-5] Study of the switching from fingolimod to dimethyl fumarate in multiple sclerosis patients

Takamichi Sugimoto¹, Roi Ishikawa¹, Taku Tazuma¹, Masahiro Hayashi¹, Naoko Mine¹, Haruka Ishibashi¹, Kazuhide Ochi², Eiichi Nomura¹, Tatsuo Kohriyama³, Takemori Yamawaki¹ (1.Department of Neurology, Hiroshima City Hiroshima Citizens Hospital, 2.Department of Neurology, Hiroshima City Asa Citizens Hospital, 3.Department of Neurology, Brain Attack Center, Ota Memorial Hospital)

[Pj-021-6] The Safety Results of Dimethyl Fumarate from Post Marketing Surveillance in Japan

Hirofumi Ochi¹, Toshiyuki Fukazawa², Takashi Yamamura³, Ryusuke Sato⁴, Haruki Makioka⁴, Nami Sugiyama⁴, Michihiro Kanda⁴, Yasuhiro Onizuka⁴, Naoto Matsuda⁴, Shinichi Torii⁴ (1.Department of Geriatric Medicine and Neurology, Ehime University Graduate School of Medicine, 2.Sapporo Neurology Hospital, 3.Department of Neurology, National Center of Neurology and Psychiatry, 4.Biogen Japan Ltd)